COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Long-Quan Li, Tian Huang, Yong-Qing Wang, Zheng-Ping Wang, Yuan Liang, Tao-Bi Huang, Hui-Yun Zhang, Weiming Sun, Yuping Wang, Long-Quan Li, Tian Huang, Yong-Qing Wang, Zheng-Ping Wang, Yuan Liang, Tao-Bi Huang, Hui-Yun Zhang, Weiming Sun, Yuping Wang

Abstract

The aim of this study was to analyze the clinical data, discharge rate, and fatality rate of COVID-19 patients for clinical help. The clinical data of COVID-19 patients from December 2019 to February 2020 were retrieved from four databases. We statistically analyzed the clinical symptoms and laboratory results of COVID-19 patients and explained the discharge rate and fatality rate with a single-arm meta-analysis. The available data of 1994 patients in 10 literatures were included in our study. The main clinical symptoms of COVID-19 patients were fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%). Minor symptoms include headache or dizziness (12.1%), diarrhea (4.8%), nausea and vomiting (3.9%). The results of the laboratory showed that the lymphocytopenia (64.5%), increase of C-reactive protein (44.3%), increase of lactic dehydrogenase (28.3%), and leukocytopenia (29.4%) were more common. The results of single-arm meta-analysis showed that the male took a larger percentage in the gender distribution of COVID-19 patients 60% (95% CI [0.54, 0.65]), the discharge rate of COVID-19 patients was 52% (95% CI [0.34,0.70]), and the fatality rate was 5% (95% CI [0.01,0.11]).

Keywords: 2019-nCoV; COVID-19; clinical characteristics; discharge rate; fatality rate; meta-analysis.

Conflict of interest statement

The authors declare that there are no conflict of interests.

© 2020 Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
A flow diagram of the inclusion criteria of studies eligible for meta‐analysis
Figure 2
Figure 2
Forest plot of all the outcomes. (A, C, E) sex distribution; fatality rate; discharge rate. Funnel plot (B, D, F) sex distribution; fatality rate; discharge rate

References

    1. National Health Commission of the People's Republic of China main website. . Accessed 20 January 2020.
    1. WHO main website. . Accessed 5 February 2020.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727‐733.
    1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270‐273.
    1. Yang Y, Lu Q, Liu M, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. 2020.
    1. National Health Commission of the People's Republic of China main website. . Accessed 18 February 2020.
    1. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non‐randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712‐716.
    1. Guan W‐j, Ni Z‐y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020. 2020.2002.2006.20020974.
    1. Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323(11):1092‐1093. 10.1001/jama.2020.1623
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
    1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus‐Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061‐1069. 10.1001/jama.2020.1585
    1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med. 2020. 10.1056/NEJMoa2001316
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395(10223):507‐513.
    1. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64‐68. 10.5582/bst.2020.01030
    1. Kui L, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020. 10.1097/CM9.0000000000000744. [published online ahead of print February 7, 2020].
    1. Lei C, Huiguo L, Wei L, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberculosis Respir Dis. 2020;43(00):E013.
    1. Mingqiang Z, Xiaohui W, Kaili C, et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Chin Med J. 2020;43(3):215‐218. 10.3760/cma.j.issn.1001-0939.2020.03.015
    1. Abraham NS, Byrne CJ, Young JM, Solomon MJ. Meta‐analysis of well‐designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol. 2010;63(3):238‐245.
    1. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS‐like disease. Clin Microbiol Rev. 2015;28(2):465‐522.
    1. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017;3(11):eaao4966.
    1. Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019‐nCov infection: a bioinformatics analysis based on single‐cell transcriptomes. 2020.
    1. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS‐CoV): a systematic review and meta‐analysis. Int J Infect Dis. 2016;49:129‐133.
    1. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex‐based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046‐4053.
    1. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019;56(3):308‐321.
    1. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130‐137.
    1. Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59.
    1. Wang XF, Shi GC, Wan HY, et al. Clinical features of three avian influenza H7N9 virus‐infected patients in Shanghai. Clin Respir J. 2014;8(4):410‐416.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi